Krito, bet perspektyvios — pelningos, fwd P/E < 50, 52 sav. augimas, diena -10%+

2026-10-25 13:12
Atnaujinta: 2026-10-25 13:12

Krito, bet perspektyvios pelningos, fwd P/E < 50, 52 sav. augimas, diena -10%+

Šaltinis: Atidaryti ↗
BEY📊📈Bloom Energy Corp
193.30 USD -11.24%
Electrical Equipment & Parts · $56.9B
MCap $57.1B  |  EV $57.5B  |  P/E 254.3  |  Fwd P/E 39.1  |  Div –  |  Cash/sh $8.41  |  EPS $0.76  |  EPS next Y $4.94  |  EPS š.m. –  |  EPS kiti m. +62.7%
RSI 22.7  |  SMA20 $257.30  |  SMA50 $248.30  |  SMA200 $219.29  |  Vol (sav.) 7.6%  |  Vol (mėn.) 6.2%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS2BCOGS1.4B · 71%OpEx515M · 25%Mokesčiai / kita161M · 8%Grynasis nuostolis88M · 4%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
-192M-117M211M2022FCF -309M-373M-84M683M2023FCF -456M92M-59M175M2024FCF 33M114M-93M1.5B2025FCF 57M
1 mėn.S $189.00R $300.80O:203.0 H:206.0 L:189.0 C:193.3 V:35.9M1 mėn. -24.5%
1 m.S $157.65R $329.69O:236.8 H:253.3 L:235.6 C:252.9 V:16.5M1 m. +138.6%
5 m.S $15.15R $119.60O:96.5 H:97.0 L:75.7 C:88.8 V:78.3M5 m. +251.8%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -12.66%
1mėn -27.51%
3mėn +2.72%
YTD +122.47%
Vol 36.02M
RelVol 2.30
⚡ AI ANALIZĖ
Bloom Energy atiteko į „krito, bet perspektyvios“ kategoriją: -11 % po rekordinių Q3 rezultatų (rinką gąsdino pinigų srautai, ne pajamos), o gidai pakelti. Fundamentinė istorija — duomenų centrų energijos paklausa — nesikeitė; artėja įtraukimas į S&P 500, kas pridės indeksų pirkimų. Rizikos: vertinimas labai aukštas po šių metų kilimo ir jautrumas AI capex sentimentui. Katalizatoriai: laisvų pinigų srautų pagerėjimas ir nauji duomenų centrų kontraktai.
CORTY📊📈Corcept Therapeutics Inc
85.86 USD -20.13%
Biotechnology · $9.3B
MCap $9.3B  |  EV $9.0B  |  P/E 190.8  |  Fwd P/E 19.5  |  Div –  |  Cash/sh $2.85  |  EPS $0.45  |  EPS next Y $4.41  |  EPS š.m. +24.1%  |  EPS kiti m. +107.8%
RSI 16.6  |  SMA20 $114.69  |  SMA50 $115.21  |  SMA200 $73.55  |  Vol (sav.) 9.8%  |  Vol (mėn.) 5.0%
💰 PINIGŲ SRAUTAS · 2025
PAJAMOS761MCOGS13M · 2%OpEx704M · 92%Grynasis pelnas100M · 13%
💵 CASH FLOW● operacinė ● investicinė ● finansavimo
120M-114M-17M2022FCF 120M127M91M-149M2023FCF 127M198M-178M-28M2024FCF 196M142M70M-220M2025FCF 142M
1 mėn.S $84.13R $122.81O:106.1 H:106.1 L:84.1 C:85.9 V:3.1M1 mėn. -23.2%
1 m.S $79.22R $126.38O:110.6 H:112.1 L:109.3 C:111.6 V:0.6M1 m. +51.7%
5 m.S $49.00R $89.00O:88.7 H:89.0 L:78.1 C:83.8 V:8.1M5 m. +348.9%
Dienos zvakes + Bollinger Bands (realus laikas)
1sav -22.06%
1mėn -27.55%
3mėn -5.77%
YTD +146.72%
Vol 3.10M
RelVol 2.60
🤖 TradingAgents CFD: NIEKO NEDARYTI (ataskaita nuo 2026-10-02, prieš 23 d.) pilna ataskaita ↗
Hold
🎫 Trade Plan
🎯 Action: Hold💵 Entry: –🛑 Stop: 109.0
Position sizing:

Maintain current allocation; cap position at a size the portfolio could withstand through a 25–30% adverse catalyst gap. Do not add.

Reasoning:

CORT's secular uptrend remains intact (price 63% above the 200 SMA at $69.78, 50 SMA rising every session to $112.61) and the five-week flag between ~$108 and $120 shows bullish consolidation behavior (RSI 50.5 holding the 45–58 band, no distribution volume). However, short-term momentum has rolled over — price sits below the 10 EMA ($114.80), MACD has crossed below signal with a negative histogram, and repeated failures above $120 warn that timing for new longs is unconfirmed. The research plan's fundamentals are mixed (strong Korlym franchise and cash position versus unproven Lifyorli ramp, 97% receivables growth, and dependence on year-end FDA/EMA binary events), so neither aggressive initiation nor exit is warranted. Hold existing exposure with a protective stop just below the $108–110 support shelf (~2x ATR under the mid-band, a $109 stop is ~4.4% below the $114.03 close); a decisive close below that shelf triggers the planned 25–33% reduction, while adds require confirmed breakout above ~$120.5 plus Q3 revenue, receivables, and regulatory validation.

📊 Techninė analizė (5)
Executive Summary

CORT has undergone a massive, sustained uptrend — roughly tripling from ~$40 in early April 2026 to a peak of ~$123.57 (2026-08-25) — and has spent the last ~5 weeks in a high-level consolidation/bullish flag between roughly $108 and $120. The stock sits at a decision point: the long-term trend remains powerfully bullish, but short-term momentum has stalled and is actively deteriorating at the margins.

Indicators selected (8, non-redundant): `close_200_sma`, `close_50_sma`, `close_10_ema`, `macd` (+ signal/histogram read from the verified snapshot), `rsi`, `boll` (middle, with upper/lower bands from snapshot), `atr`, `vwma`. This set spans trend (3 horizons), momentum (2), volatility/range (2), and volume-price confirmation (1) — each answering a distinct question about the current regime.

---

Trend Analysis (MA)

| Horizon | Indicator (10-01 value) | Price Relationship | Interpretation |

|---|---|---|---|

| Long-term | 200 SMA: $69.78 | Price +63% above | Secular uptrend fully intact |

| Medium-term | 50 SMA: $112.61 | Price +1.2% above | Trend intact but flattening base |

| Short-term | 10 EMA: $114.80 | Price −0.7% below | Momentum has rolled over |

  • The 50 SMA has risen every single session from $84.82 (08-03) to $112.61 (10-01) — an unbroken ~$28 climb over two months. This is a strong dynamic support shelf. The 200 SMA has similarly ground higher from $62.01 to $69.78. There is no death-cross risk whatsoever; the moving-average stack remains perfectly ordered (10 EMA > 50 SMA > 200 SMA).
  • Key nuance: price closed at $114.03, marginally below the 10 EMA ($114.80) for the most recent session after oscillating around it since mid-September. The 10 EMA itself has gone flat (~$114.8–115.0 for the last week), confirming short-term momentum exhaustion rather than active distribution.
  • The 50 SMA at ~$112.6 and the VWMA at ~$113.1 form a confluent support zone ($112.5–113.5) that has absorbed every pullback since early September.

Verdict: Strategic trend = bullish. Tactical trend = neutral/slightly soft.

Momentum (MACD & RSI)
  • RSI: 50.54 — dead-neutral. This is a dramatic normalization from the 72+ readings in late August (peak overbought zone 08-21 to 08-25). Importantly, during the entire September consolidation RSI has held the 45–58 band, never dipping below ~46.6 (09-18). This is classic bullish consolidation behavior — sellers have been unable to push momentum into oversold territory.
  • MACD: 0.89 vs. Signal 1.09 → Histogram −0.20 — the MACD line crossed below its signal line and the histogram has gone negative. The MACD line has collapsed from a peak of 7.23 (08-25) to 0.89 — a ~88% decay. While MACD remains above zero (no trend-reversal signal), the bearish crossover warns that upside impetus has faded. Momentum traders should treat this as a yellow flag, not a sell trigger, given the zero-line support.
Volatility (BB & ATR)
  • ATR: 5.23 — down from 6.06 (08-03) and well off the spike highs seen around the 07-30 gap (the $92.95→$118.32 candle on 4.5M volume). Volatility is contracting as the flag forms — typical and constructive.
  • Bollinger snapshot: Middle $113.99 | Upper $118.33 | Lower $109.65 — price ($114.03) sits essentially on the mid-band, with the bands relatively tight (bandwidth ≈ 7.6% of price). The market is coiling. The late-August breakdown from the upper band (~$126) to the lower region was orderly, and price has since mean-reverted to the middle — equilibrium.
  • Notable: the 09-18 session printed 17.23M volume (vs. typical ~0.6–1.5M) with a wide range ($108.41–$117.90) closing at $110.29 — an institutional-scale churn day that resolved sideways rather than downward, suggesting absorption.
Actionable Insights

Support levels (evidence-based):

  • $112.5–113.5 — 50 SMA ($112.61) + VWMA ($113.10) confluence; also the 09-08 and 09-23 reaction lows zone.
  • $109.6–110.8 — Bollinger lower band ($109.65) + the 09-18 ($110.29) and 09-15 ($110.82) closes.
  • A decisive break of ~$108 (lower band region, 09-02 low $108.73) would target the rising 50 SMA gap-fill toward $105, and potentially the $100 round number.

Resistance levels:

  • $118.3 — Bollinger upper band + 09-24 high ($119.15) + 09-29 high ($120.51) zone.
  • $120.4–123.6 — 09-25 high ($120.44), 08-24/08-25 double-top ($123.24/$123.57). A breakout above $123.57 on expanding volume re-opens the trend.

Trade plan:

  • Existing holders (HOLD): the secular uptrend and orderly consolidation argue for patience. A trailing stop below the $108–110 zone (roughly 2× ATR under the mid-band) protects against a trend break while allowing the flag to resolve.
  • New entries: momentum traders should wait for either (a) a close above ~$118.3–120.5 with MACD histogram turning positive, or (b) a pullback to the $110–112.5 shelf where RSI resets toward 40–45 with a bullish reversal candle.
  • Risk: biotech headline risk is inherent; position size per ATR (5.23 ≈ 4.6% of price) — e.g., a $109 stop is ~4.4% below current price.
⚡ AI ANALIZĖ
Corcept Therapeutics krito dėl FDA CRL relacorilantui ir Genmab konkurencinių duomenų, bet pagrindinė Korlym franšizė vis dar generuoja pajamas, o onkologijos programa (ASCO 2026 duomenys su bendru išgyvenamumu platiniai atspariame kiaušidžių vėžyje) išlieka perspektyvi. Akcija kritusi >50 % nuo piko — dalis rinkos jau įkainavo blogiausią scenarijų. Rizikos: relacorilanto kelias per FDA neaiškus ir gali pareikalauti naujo tyrimo. Katalizatoriai: FDA susitikimo rezultatai ir relacorilanto onkologijos klinikiniai duomenys.